- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Table of Contents
Volume 2012 (2012), Article ID 729821, 4 pages
Effect of Heamolysis on Prostate-Specific Antigen
1Department of Urology, Sakarya University, Medical Faculty, Sakarya, Turkey
2Department of Urology, Sakarya Training and Research Hospital, Kemalpaşa Mah, 222 Sokak, ATA-8, Sitesi, No. 9/3, Serdivan, Turkey
3Department of Biochemistry, Sakarya Training and Research Hospital, Sakarya, Turkey
Received 21 October 2012; Accepted 8 November 2012
Academic Editors: P.-L. Chang, J. I. Izawa, and J. H. Ku
Copyright © 2012 Hasan S. Sağlam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- A. A. Haroun, A. S. Hadidy, Z. M. Awwad, C. F. Nimri, W. S. Mahafza, and E. S. Tarawneh, “Utility of free prostate specific antigen serum level and its related parameters in the diagnosis of prostate cancer,” Saudi Journal of Kidney Diseases and Transplantation, vol. 22, pp. 291–297, 2011.
- A. Semjonow, F. Oberpenning, B. Brandt, C. Zechel, W. Brandau, and L. Hertle, “Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen,” Urology, vol. 48, no. 6, pp. 10–15, 1996.
- A. E. Pelzer, H. Volgger, J. Bektic et al., “The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels,” BJU International, vol. 96, no. 7, pp. 995–998, 2005.
- B. E. Sirovich, L. M. Schwartz, and S. Woloshin, “Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?” Journal of the American Medical Association, vol. 289, no. 11, pp. 1414–1420, 2003.
- K. Uchida, H. Takeshima, H. Akaza, and Y. Ono, “Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system,” Japanese Journal of Clinical Oncology, vol. 30, no. 2, pp. 95–100, 2000.
- J. Walz, A. Haese, V. Scattoni et al., “Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower,” Cancer, vol. 113, no. 10, pp. 2695–2703, 2008.
- L. Nogueira, R. Corradi, and J. A. Eastham, “Prostatic specific antigen for Prostate Cancer detection,” International Brazilian Journal of Urology, vol. 35, no. 5, pp. 521–529, 2009.
- G. Sölétormos, A. Semjonow, P. E. C. Sibley et al., “Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice,” Clinical Chemistry, vol. 51, no. 8, pp. 1342–1351, 2005.
- H. B. Carter, L. Ferrucci, A. Kettermann et al., “Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability,” Journal of the National Cancer Institute, vol. 98, no. 21, pp. 1521–1527, 2006.
- B. Laxman, D. S. Morris, J. Yu et al., “A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer,” Cancer Research, vol. 68, no. 3, pp. 645–649, 2008.
- A. Tekin, N. Atsu, and H. Ozen, “Daily variability of serum prostate-specific antigen in men over 50 years of age,” International Urology and Nephrology, vol. 33, no. 4, pp. 641–644, 2001.
- L. Cohen, R. T. Fouladi, R. J. Babaian et al., “Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program,” Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 7, pp. 610–617, 2003.
- G. M. Oremek and U. B. Seiffert, “Physical activity releases prostate-specific antigen (PSA) from the prostate gland into blood and increases serum PSA concentrations,” Clinical Chemistry, vol. 42, no. 5, pp. 691–695, 1996.
- M. H. Kroll and R. J. Elin, “Interference with Clinical Laboratory analyses,” Clinical Chemistry, vol. 40, pp. 1996–2005, 1994.
- G. Lippi, M. Franchini, M. Montagnana, G. L. Salvagno, G. Poli, and G. C. Guidi, “Quality and reliability of routine coagulation testing: can we trust that sample?” Blood Coagulation and Fibrinolysis, vol. 17, no. 7, pp. 513–519, 2006.
- G. Lippi, N. Blanckaert, P. Bonini et al., “Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories,” Clinical Chemistry and Laboratory Medicine, vol. 46, no. 6, pp. 764–772, 2008.
- J. A. Snyder, M. W. Rogers, M. S. King, J. C. Phillips, J. F. Chapman, and C. A. Hammett-Stabler, “The impact of hemolysis on Ortho-Clinical Diagnostic's ECi and Roche's elecsys immunoassay systems,” Clinica Chimica Acta, vol. 348, no. 1-2, pp. 181–187, 2004.
- G. Lindstedt, A. Jacobsson, P. A. Lundberg, H. Hedelin, S. Pettersson, and B. Unsgaard, “Determination of prostate-specific antigen in serum by immunoradiometric assay,” Clinical Chemistry, vol. 36, no. 1, pp. 53–58, 1990.